Skip Navigation Links
SEARCH  



 
Bookmark and Share
The Business Insider: The Money Game Eli Lilly jumps 10% after it says it will seek approval for its Alzheimer's drug following designation as a breakthrough therapy by the FDA
Goldman Sachs said Eli Lilly's decision to seek accelerated approval for donanemab was ahead of its expectations.

Full "The Business Insider: The Money Game" article




Disclaimer | Terms Of Use And Privacy Statement


© Metals News. All rights reserved.